STAA vs. RXST, EYE, WRBY, BLCO, ICUI, TDOC, PDCO, LFST, ARVN, and CORT
Should you be buying STAAR Surgical stock or one of its competitors? The main competitors of STAAR Surgical include RxSight (RXST), National Vision (EYE), Warby Parker (WRBY), Bausch + Lomb (BLCO), ICU Medical (ICUI), Teladoc Health (TDOC), Patterson Companies (PDCO), LifeStance Health Group (LFST), Arvinas (ARVN), and Corcept Therapeutics (CORT). These companies are all part of the "medical" sector.
RxSight (NASDAQ:RXST) and STAAR Surgical (NASDAQ:STAA) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.
78.8% of RxSight shares are owned by institutional investors. Comparatively, 96.7% of STAAR Surgical shares are owned by institutional investors. 21.1% of RxSight shares are owned by insiders. Comparatively, 1.1% of STAAR Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, STAAR Surgical had 4 more articles in the media than RxSight. MarketBeat recorded 7 mentions for STAAR Surgical and 3 mentions for RxSight. STAAR Surgical's average media sentiment score of 0.83 beat RxSight's score of 0.78 indicating that RxSight is being referred to more favorably in the media.
RxSight has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.
STAAR Surgical has a net margin of 6.62% compared to STAAR Surgical's net margin of -54.57%. RxSight's return on equity of 8.73% beat STAAR Surgical's return on equity.
STAAR Surgical received 253 more outperform votes than RxSight when rated by MarketBeat users. However, 63.27% of users gave RxSight an outperform vote while only 56.35% of users gave STAAR Surgical an outperform vote.
RxSight currently has a consensus target price of $49.63, suggesting a potential downside of 8.61%. STAAR Surgical has a consensus target price of $46.38, suggesting a potential upside of 1.86%. Given RxSight's higher possible upside, analysts clearly believe STAAR Surgical is more favorable than RxSight.
STAAR Surgical has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.
Summary
STAAR Surgical beats RxSight on 11 of the 18 factors compared between the two stocks.
Get STAAR Surgical News Delivered to You Automatically
Sign up to receive the latest news and ratings for STAA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
STAAR Surgical Competitors List
Related Companies and Tools
